IPO - PALISADE BIO, INC.

Form Type: S-1

Filing Date: 2025-05-27

Corporate Action: Ipo

Type: New

Accession Number: 000164117225012405

Filing Summary: Palisade Bio, Inc. filed a registration statement on Form S-1 with the SEC on May 27, 2025, to offer up to 13,140,604 shares of common stock and pre-funded warrants to purchase up to the same number of common stock shares, plus additional shares issuable upon exercise of underwriter warrants. The offering aims to raise capital primarily for the continued development of PALI-2108, its lead product candidate targeted at treating inflammatory bowel disease (IBD). This offering comes after the company announced positive results from its Phase 1 clinical trial for PALI-2108, indicating its potential as a first-in-class therapy for conditions like fibrostenotic Crohn’s disease and ulcerative colitis. Palisade expects to commence public sales as soon as possible following the effectiveness of the registration statement, highlighting investor interest in this clinical-stage biopharmaceutical's innovative therapies designed to address significant unmet medical needs. The company also identifies itself as a smaller reporting company and has stated its strategy focuses on the advancement of product candidates for autoimmune and inflammatory conditions.

Form Type: DRS

Filing Date: 2025-05-05

Corporate Action: Ipo

Type: New

Accession Number: 000164117225008698

Filing Summary: Palisade Bio, Inc. has submitted a draft registration statement for a public offering under the Securities Act of 1933 on May 5, 2025, seeking to raise capital through the sale of common stock and pre-funded warrants. The offering aims to raise funds to further develop its lead product candidate, PALI-2108, focused on treating autoimmune and inflammatory diseases, particularly inflammatory bowel disease (IBD). This includes details about the structure of the offering, potential pricing, the company's strategy to develop a biomarker-based patient selection approach for PALI-2108, and insights into the clinical trials that are ongoing or planned. The document also outlines a recent notice from Nasdaq regarding the minimum bid price requirement for continued listing, emphasizing the company's proactive approach to addressing compliance with listing standards. The anticipated timeline for the initiation of sales is as soon as practicable after the registration statement is effective, with an indication of risk factors associated with investing in the company's securities.

Form Type: CORRESP

Filing Date: 2024-12-10

Corporate Action: Ipo

Type: New

Accession Number: 000149315224049440

Filing Summary: Ladenburg Thalmann & Co. Inc. has submitted a concurrence in the request made by Palisade Bio, Inc. to accelerate the effective date of its Registration Statement on Form S-1 (Registration No. 333-282883) to December 11, 2024, at 5:30 p.m. Eastern Time. This acceleration is pursued under Rule 461 of the Securities Act, indicating that Palisade Bio, Inc. is moving forward with an initial public offering (IPO). Ladenburg has confirmed its awareness of the obligations involved in this offering.

Form Type: CORRESP

Filing Date: 2024-12-10

Corporate Action: Ipo

Type: New

Accession Number: 000149315224049441

Filing Summary: Palisade Bio, Inc. is requesting the Securities and Exchange Commission to take action on its Registration Statement on Form S-1, which was originally filed on October 30, 2024. The company aims for the registration statement to become effective at 5:30 p.m. Eastern Time on December 11, 2024. The filing is part of the process for an initial public offering (IPO).